VRTX | NASDAQ
Next Earnings: Jul 24, 2026
Company Overview:
10 Year VRTX Performance Metrics:
Unlock All Reports & Research Dividend Stocks.
[lev_ptables no_sale]VRTX Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for VRTX
Based on past 10-year performance, here are VRTX growth metrics:
Share price CAGR of +17.55%
Dividend CAGR of +0%
Using VRTX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| VRTX (DRIP) | VRTX - No DRIP | |
|---|---|---|
| Current Price | $473.09 | $473.09 |
| Start Shares | 21.14 | 21.14 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 21.14 | 21.14 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $2,383.79 | $473.09 |
| Total Dividends | $0 | $0 |
| Final Value | $50,388 | $10,000 |
NOTE: Above numbers are our estimate based on VRTX's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
[lev_ptables no_sale]Company Info
Vertex Pharmaceuticals Incorporated (VRTX) had its IPO on 1991-07-24, and is trader on NASDAQ stock exchange.
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
VRTX website: https://www.vrtx.com
